Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model

Patients with Parkinson’s disease (PD) have impaired insulin signaling in the brain. Incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), can re-sensitize insulin signaling. In a recent phase II clinical trial, the first GLP-1 mimic, ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ling-Yu, Jin, Qian-Qian, Hölscher, Christian, Li, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323666/
https://www.ncbi.nlm.nih.gov/pubmed/33433498
http://dx.doi.org/10.4103/1673-5374.303045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323666/
https://www.ncbi.nlm.nih.gov/pubmed/33433498
http://dx.doi.org/10.4103/1673-5374.303045

Ejemplares similares